Metronomic chemotherapy—the low-dose, long term and frequently administered chemotherapy—has revealed in these years an important impact on the stabilization of cancer disease for its known antiangiogenic effects, prolonged clinical benefits and the improved quality of life of several cancer patients, without any high grade toxicity [1–3]. Both the low cost and the oral administration of the drugs are key characteristics of this schedule and may offer important social advantages [4]. Anecdotical case reports [5–7] and experiences in small subsets of patients enrolled in retrospective clinical studies [8–10] on metastatic cancers have been recently published about the use of metronomic therapy as a first-line treatment. These point out the possible importance of metronomic chemotherapy as an alternative approach to first-line therapy in frail patients requiring palliation or patients refusing the standard chemotherapy for its impact on the quality of life. However, no data of prospective clinical trials on first line metronomic chemotherapy are currently available in metastatic cancer human patients. The veterinary medical oncology has advanced dramatically over the past few decades, because of the successful application of a number of conventional chemotherapeutic drugs to the cancer conditions diagnosed in veterinary patients [11]. Veterinary oncology cases often present a unique opportunity to investigate novel drugs and treatment schedules providing many in vivo information to the larger medical community and giving new effective options for dogs themselves [12]. As well recently pointed out by Paoloni and Khanna [13], these studies may also have a great translational relevance, predicting new therapies and related surrogate markers in human beings because pet dogs with cancers might assist the transition between mouse models and human patients. Moreover, in the clinical practice, veterinarians and their clients are generally less willing to accept a high degree of side effects, which most often results in lower drug doses than the ones that are used in human oncology. The aim of the present pilot study was to test a first-line metronomic oral combination of cyclophosphamide (CTX) and celecoxib (CXB) in canine metastatic spontaneous tumours, characterizing possible biomarkers to translate in human clinical research.
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study
MARCHETTI, VERONICA;GIORGI, MARIO;CITI, SIMONETTA;ORLANDI P;DI DESIDERO T;DANESI, ROMANO;BOCCI, GUIDO
2012-01-01
Abstract
Metronomic chemotherapy—the low-dose, long term and frequently administered chemotherapy—has revealed in these years an important impact on the stabilization of cancer disease for its known antiangiogenic effects, prolonged clinical benefits and the improved quality of life of several cancer patients, without any high grade toxicity [1–3]. Both the low cost and the oral administration of the drugs are key characteristics of this schedule and may offer important social advantages [4]. Anecdotical case reports [5–7] and experiences in small subsets of patients enrolled in retrospective clinical studies [8–10] on metastatic cancers have been recently published about the use of metronomic therapy as a first-line treatment. These point out the possible importance of metronomic chemotherapy as an alternative approach to first-line therapy in frail patients requiring palliation or patients refusing the standard chemotherapy for its impact on the quality of life. However, no data of prospective clinical trials on first line metronomic chemotherapy are currently available in metastatic cancer human patients. The veterinary medical oncology has advanced dramatically over the past few decades, because of the successful application of a number of conventional chemotherapeutic drugs to the cancer conditions diagnosed in veterinary patients [11]. Veterinary oncology cases often present a unique opportunity to investigate novel drugs and treatment schedules providing many in vivo information to the larger medical community and giving new effective options for dogs themselves [12]. As well recently pointed out by Paoloni and Khanna [13], these studies may also have a great translational relevance, predicting new therapies and related surrogate markers in human beings because pet dogs with cancers might assist the transition between mouse models and human patients. Moreover, in the clinical practice, veterinarians and their clients are generally less willing to accept a high degree of side effects, which most often results in lower drug doses than the ones that are used in human oncology. The aim of the present pilot study was to test a first-line metronomic oral combination of cyclophosphamide (CTX) and celecoxib (CXB) in canine metastatic spontaneous tumours, characterizing possible biomarkers to translate in human clinical research.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
